
Eagle Pharmaceuticals EGRX
Quarterly report 2023-Q2
added 08-08-2023
Eagle Pharmaceuticals Cash Conversion Cycle 2011-2025 | EGRX
Annual Cash Conversion Cycle Eagle Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 139 | 140 | 112 | 96.1 | 104 | 39.2 | 2.23 | 406 | 53.3 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 406 | 2.23 | 121 |
Quarterly Cash Conversion Cycle Eagle Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 308 | 276 | - | 320 | 237 | 96.3 | - | 60.3 | 43.2 | 85.2 | - | 112 | 126 | 126 | 90.8 | 115 | 82.8 | 102 | 108 | 101 | 91.8 | 64.2 | 105 | -52.1 | 27.7 | 57 | 47.5 | -3.07 | -1.16 | 103 | 132 | 690 | 704 | 116 | 79.2 | 293 | 55.9 | 78.3 | 22.2 | 27.3 | 27.5 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 704 | -52.1 | 133 |
Cash Conversion Cycle of other stocks in the Drug manufacturers industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
-128 | - | - | $ 142 M | ||
|
Assertio Holdings
ASRT
|
327 | $ 0.75 | -2.02 % | $ 53.3 M | ||
|
Cronos Group
CRON
|
213 | $ 3.09 | -5.64 % | $ 1.66 B | ||
|
Aerie Pharmaceuticals
AERI
|
460 | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
177 | $ 1.66 | -4.48 % | $ 179 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
-58.9 | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-224 | - | 0.86 % | $ 117 M | ||
|
Agile Therapeutics
AGRX
|
-206 | - | 10.11 % | $ 58.2 M | ||
|
Aurora Cannabis
ACB
|
1.45 K | $ 5.22 | -3.33 % | $ 86.3 M | ||
|
Catalent
CTLT
|
110 | - | - | $ 11.5 B | ||
|
HEXO Corp.
HEXO
|
775 | - | 2.45 % | $ 38.1 M | ||
|
DURECT Corporation
DRRX
|
41.4 | - | - | $ 50.1 M | ||
|
Endo International plc
ENDP
|
141 | - | - | $ 28.9 M | ||
|
Emergent BioSolutions
EBS
|
181 | $ 11.91 | 4.29 % | $ 610 M | ||
|
Organogenesis Holdings
ORGO
|
64.5 | $ 4.91 | 1.76 % | $ 647 M | ||
|
Pacira BioSciences
PCRX
|
209 | $ 26.42 | 0.49 % | $ 1.22 B | ||
|
Evoke Pharma
EVOK
|
45.7 | $ 10.97 | 0.18 % | $ 36.7 M | ||
|
Athenex
ATNX
|
137 | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
192 | $ 21.45 | 0.4 % | $ 2.04 B | ||
|
Rockwell Medical
RMTI
|
45 | $ 0.9 | -2.78 % | $ 21 M | ||
|
Evolus
EOLS
|
74.6 | $ 7.2 | 2.2 % | $ 447 M | ||
|
Harrow Health
HROW
|
-86.6 | $ 46.39 | -1.43 % | $ 1.51 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
150 | $ 3.55 | -1.11 % | $ 4.41 M | ||
|
China Pharma Holdings
CPHI
|
164 | $ 1.53 | -1.92 % | $ 26.7 M | ||
|
Bausch Health Companies
BHC
|
78.9 | $ 6.79 | -1.95 % | $ 2.48 B | ||
|
Veru
VERU
|
6.7 | $ 2.39 | -1.15 % | $ 322 M | ||
|
Lannett Company
LCI
|
173 | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
2.92 K | $ 1.85 | -3.91 % | $ 402 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-161 | $ 2.96 | 17.0 % | $ 41.6 M | ||
|
PetIQ
PETQ
|
53.8 | - | 1.64 % | $ 400 M | ||
|
Jupiter Wellness
JUPW
|
-21.1 | - | - | $ 33.6 M | ||
|
Perrigo Company plc
PRGO
|
138 | $ 12.99 | -1.14 % | $ 1.78 B | ||
|
ProPhase Labs
PRPH
|
96 | $ 0.11 | -0.35 % | $ 1.74 M | ||
|
Radius Health
RDUS
|
-53.5 | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
105 | - | -4.76 % | $ 65.3 M | ||
|
cbdMD
YCBD
|
92 | $ 1.59 | 30.33 % | $ 6.86 M | ||
|
OptiNose
OPTN
|
314 | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
111 | - | -27.8 % | $ 2.56 M | ||
|
SCYNEXIS
SCYX
|
106 | $ 0.64 | -1.49 % | $ 30.6 M | ||
|
Tilray
TLRY
|
169 | $ 11.19 | -7.9 % | $ 6.92 B | ||
|
TherapeuticsMD
TXMD
|
-723 | $ 1.74 | -0.86 % | $ 18.2 M | ||
|
Zomedica Corp.
ZOM
|
196 | - | -0.21 % | $ 98 M | ||
|
Viatris
VTRS
|
155 | $ 11.71 | 0.47 % | $ 14.2 B |